Navigation Links
AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
Date:3/7/2008

LARGO, Fla., March 7 /PRNewswire/ -- AlphaMed Pharmaceuticals Corporation announced today that the Company has successfully expressed a humanized version of the therapeutic protein alpha 1-antitrypsin (AAT). AlphaMed scientists expressed their recombinant AAT utilizing the Company's proprietary production system in yeast. The yeast has been genetically altered to produce a molecule "virtually identical" to that which is manufactured by the human body.

"This marks a major milestone for this company and AAT research," stated Joseph McGuirl, AlphaMed's CEO, "AlphaMed is the first company to develop an AAT molecule with glycosylation that resembles the human protein that is naturally secreted from the liver. The Company has begun to develop products to treat a variety of diseases including hereditary emphysema, COPD, asthma and cystic fibrosis." Joseph McGuirl joined AlphaMed in July, 2007 and is the former Head of Licensing and Development for Hoffmann-LaRoche.

"I am glad to confirm that the work progressed well so far," stated Dr. Roland Contreras Ph.D. of the VIB, University of Ghent located in Belgium who has been supervising AlphaMed's molecular biology. "The two complex sugars of the left arm have been added with good efficiency. This is an important milestone and in my opinion a glycoform worth purifying. It is a mammalian hybrid form."

Plasma-derived AAT is currently marketed by several companies for the treatment of hereditary emphysema and generates over $200 Million in revenues, annually. The plasma-derived AAT, however, is marked by shortages and blood contamination risks.

In addition, AAT plays a vital role in the inflammatory cascade and in many instances can act as a replacement for conventional steroids. Additional disease indications treatable by AAT therapy include atopic dermatitis, psoriasis, rheumatoid arthritis and others. "The market potential for AAT therapies is in the billions," stated McGuirl, "and given AlphaMed's intellectual property position this news represents a major leg up for the company".

AlphaMed is currently seeking developmental partners to continue its research for both topical and injectible/inhalable AAT therapies. The Company has successfully completed its second round of financing and has initiated a third round to complete Phase I clinical trials and initiate Phase II clinicals.

AlphaMed Pharmaceuticals Corporation is a privately held biopharmaceutical company located in Largo, Florida. Incorporated in 1999, the Company is dedicated to the successful development of both pharmaceutical and over-the counter products for human and animal use. AlphaMed's product pipeline includes AAT for pulmonary and dermatological use as well as cromolyn sodium for a variety of topical indications. AlphaMed expects its first product to market in early 2009.


'/>"/>
SOURCE AlphaMed Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... The San Juan Capistrano summer camp team ... report outlining the need for summer camps to provide physical activities for all campers. To ... Activity In Summer Camps , With an increase in specialty camps that focus on what ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 ... proportion of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA ... Record (AOR) for Theravent, Inc. , the makers of a revolutionary new ... Consumer Healthcare, is now working to expand distribution in anticipation of a national ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is a group ... mental health struggles. The Alive team uses advanced behavioral sciences treatment modalities to ... with a mental health struggle is based on 10 modalities of treatment ...
Breaking Medicine News(10 mins):